Clinical Trials Data from Pharma Butrans Presented at APS Annual Meeting

Purdue Pharma L.P. will demonstrate an analysis of data from completed clinical trials for Butrans Transdermal System CIII with the American Pain Society's (APS) 31st Annual Scientific Seminar. The research has an evaluation of supplemental analgesic use and pain marks along the 7-day dosing interval.

The poster will probably be presented with the APS meeting in Honolulu, HI on Friday, May 18 at 8:45 AM HAST: Butrans (buprenorphine) Transdermal Structure and 7-day Analgesic Performance.

Butrans is indicated for the administration of moderate-to-severe chronic pain in affected individuals requiring endless, hysterical opioid analgesic for some time. Accepted by the U.S. Food and Drug Administration (FDA) in June 2010, Butrans is the first transdermal structure that in fact delivers steady release of a typical active component, buprenorphine, for one week.

Butrans is a Schedule III opioid medication and might be abused in a manner similar to other opioid agonists, official or illicit. Engaging with the FDA, Purdue Pharma L.P. created a Risk Evaluation and Mitigation Strategy (REMS) for Butrans that includes a Treatment Guide, Factors to make certain Safe Use, for instance a healthcare provider training manual, and a timetable for submitting evaluations of typical REMS.

Member of Receptos is Ready to Deliver Scientific Sodium Presentation

Receptos Inc. introduced that in fact company team members is going to deliver a scientific podium presentation about RPC1063 near the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 along at the San Diego Convention Center in San Diego, California. DDW interests a large number of physicians, scientists, and academics from worldwide to share the most contemporary research in gastrointestinal health matters, for which actually DDW is the premier scientific meeting. Based on an abstract entitled "A small particle S1P1 receptor agonist with major efficacy in animal types of inflammatory bowel disease (IBD)," Receptos scientific team members will talk about positive preclinical data with RPC1063 in two distinct in vivo types of IBD.

"Based on exciting statistics from each of these preclinical studies, in addition to data from a recently completed Phase 1 clinical safety learn, Receptos will initiate a Phase 2 clinical trial along with RPC1063 in 2012 in inflammatory bowel disorder," said Faheem Hasnain, President and Chief Executive Officer of Receptos. "The approval of these preclinical efficacy data for preview at DDW underscores the necessity of efficacious oral treatments for therapeutic treatment of IBD and the exhilaration on behalf of scientific and medical professionals to review the novel profile of RPC1063 in affected individuals suffering from this devastating disorder."

Brain Activities Increased in Children and Adolescents by Oxytocin

Preliminary outcomes from an ongoing, large-scale survey by Yale School of Medicine scientists has shown that oxytocin - a naturally happening substance generated in the brain and through the entire body- increased mind function in regions which are known to procedure social information in children and teenagers with autism spectrum disorders (ASD).

A Yale Child Study Center study group that features postdoctoral fellow Ilanit Gordon and Kevin Pelphrey, the Harris Associate Professor of Child Psychiatry and Psychology, will demonstrate the outcomes on Saturday, May 19 at 3 p.m. at the International Meeting for Autism Research.

"Our findings provide you with the first, critical steps towards devising more practical treatment options for core social deficits in autism that might involve a mixture of clinical interventions with a supervision of oxytocin," said Gordon. "Such a treatment method would fundamentally increase our understanding of autistic behavior along with its treatment."

Social-communicative complications certainly are a core characteristic of autism, a neurodevelopment disorder that may have an enormous psychological and financial burden on the affected individual, their own families, and society.

Gordon declared while a good amount of progress has been received in the field of autism study; generally there remain few effective therapies and none that directly targeted the core social dysfunction. Oxytocin just recently received captivation with its involvement in maintaining social abilities due to its role in many elements of social behavior and social cognition in humans as well as other species.

To determine the effect of oxytocin on the brain function, Gordon and her group performed a first-of-its-kind, double-blind, placebo-controlled survey on children and teenagers aged 7 to 18 with ASD. The group associates gave the children a single treatment of oxytocin in a nasal spray and used sensible magnetic resonance brain imaging to look at its result.

The team discovered that oxytocin increased activations in brain regions believed to process social data. Gordon said these brain activations were connected to objectives involving numerous social information development routes, for example seeing, hearing, and processing data relevant to understanding other people.

POZEN Unveils Data from PA32540 Phase 1 Gastric Acid Reduction Study

POZEN Inc. a pharmaceutical industry devoted to transforming medication that transforms lives, introduced data from a Phase 1 study that in fact found that the investigational compound, PA32540, provides faster safety in comparison to delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time and energy to gastric pH. These data have been presented initially at Digestive Disease Week (DDW) 2012 in San Diego, California with the San Diego Convention Center on May 19, 2012, at 9:15 a.m. (PT).

"In this study, the meantime to a gastric pH of higher than 4.0 was quicker along with PA32540 compared to 40 mg of delayed-release, enteric-coated omeprazole," said Philip B. Miner, Jr., M.D., President and Medical Director of a typical Oklahoma Foundation for Digestive Research and co-author of a typical study. "Moreover, the 24-hour pH control accomplished with the immediate launch type of omeprazole in PA32540 should be adequate to control over gastric acidity in patients using chronic aspirin therapy for secondary cardiovascular control."

Bullying Leads to Self-Harm in Children

Children are three times very likely to self-harm approximately the age of 12 if bullied, in accordance with new research carried out in the United Kingdom.

Bullying during early years could have damaging reactions by puberty, particularly if children are also immersed in family adversity or have emotional health troubles said the authors, who exactly suggested that in fact schools and healthcare professionals ought to aim to further “reduce bullying and begin self-harm risk-reduction programmes” with the intention to prevent the risk of bullied children annoying themselves in future life.

The medical professionals from King’s College London performed a study on just over a 1,000 pairs of twins at five, seven, 10 and 12 years of age. All children have been born in 1994-1995 in the United Kingdom and Wales. The children were evaluated on the risks of self-harm in the six months in advance of their 12th birthday. Self-harm data were actually available for 2,141 boys and girls.

A complete of 237 children was actually victims of frequent intimidating: 18 or 8 per cent of them self-harmed. Of a typical 1,904 who had not been bullied, 44 or 2 % had self-harmed.

The authors discovered that several factors improved the chance of self-harm amongst children that were bullied, including: a family history of self-harming; maltreatment; and behavioral and emotional issues.

Even though likelihood was a little bit higher for girls (1.6 %), the connection ended up being observable amongst both sexes.

Diarrhea Reduced by Consuming Probiotics

The consumption of probiotics in foods for instance yogurt will work at reducing the chance of antibiotic-associated diarrhea (AAD), says a brand new a review and meta-analysis of preceding research.

“There is definitely an increasing fascination with probiotic interventions, and indication for effectiveness of probiotics in stopping or treating AAD is likewise increasing,” said the authors that evaluated the available facts on probiotic use for these prevention or remedy for diarrhea linked to antibiotic use that may affect as much as 30 % of affected individuals.

Across 63 randomised, managed tests (n=11,811 participants), probiotic use ended up being involved with a 42 per cent lower risk of producing diarrhea in comparison to a control group not using probiotics. The answer was regular across a range of subgroup and accuracy explanations.

“Symptoms range from mild and self-limiting to acute, particularly in Clostridium difficult problems, and antibiotic-associated diarrhea is a vital reason behind non-adherence with antibiotic therapy,” in accordance with background data inside the article posted in JAMA.

A Clincal Study on Ovarian Cancer Submitted by Rexahn

Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage drug manufacturer producing and commercializing potential top in class oncology and CNS therapeutics, introduced that it has submitted a Phase II protocol for clinical study of Archexin® as a remedy of ovarian cancer towards the U.S. Food and Drug Administration (FDA).

The Phase II study can detrmine the protection and performance of Archexin especially when using in combination with both carboplatin and paclitaxel to be a second-line therapy in things which are platinum-sensitive following their personal first relapse. The research will be performed at numerous centers in the United States, and subjects will probably be randomized to obtain either carboplatin/paclitaxel or carboplatin/paclitaxel/Archexin. Various actions of clinical benefit will probably be evaluated.

Ovarian cancer would be the fifth most typical cancer among ladies, and it also causes more deaths compared to any other type of female reproductive cancer.

"Treatment solutions are limited for affected individuals that are stricken along with ovarian cancer, thus we look forward to investigating Archexin as a possible mixture treatment for the disease." said Rick Soni, President of Rexahn. "To this point, Archexin has proved potentially promising safety profile, and has been granted orphan drug designation in ovarian cancer and a number of other solid tumors from the FDA. We would like to report preliminary Phase II results away from pancreatic cancer trial along with Archexin later this season."

Risk of Suicide is Reduced by Antidepressives

Antidepressive drugs decrease the mortality rate of schizophrenic individuals, while therapy by using bensodiazepines greatly raises it, especially as regards suicide. Supplying a variety of antipsychotics concurrently, however, seems to own no effect at all. This in accordance with a new study inspecting different drug mixtures applied to affected individuals with schizophrenia.

"We weren't as aware the beneficial effects of antidepressives were therefore, powerful," says Jari Tiihonen, professor of medical psychiatry at Karolinska Institutet's Department of Clinical Neuroscience.

The research followed 2,588 Finns that had recently created schizophrenia from the time of their initial authorization to hospital for 4 years. By obtaining the Finnish registers, the scientists were consequently able to verify the effects of various drug mixes on the death rate risk inside the group.

The scientists discovered that during bensodiazepines, the individuals ran a 91 per cent greater risk of early death compared to at times when each of these drugs were not utilized. Proven the most common cause of death was suicide, and the majority deaths occurred along with patients that had been using some of their bensodiazepines for a longer time of four weeks.

A New Cancer Pill Shows Promise Against Complex Cancers

Scientists have proved than a brand new structure of cancer pill that progress the rising field of epigenetic is secure for human use, in accordance with a Phase I trial confirmed in Clinical Cancer Research.

Rather than targeting system defects in the DNA code, the medication - found in collaboration between The Institute of Cancer Research (ICR) and Chroma Therapeutics - works on cancer-causing errors in the manner the human body reads the DNA code.

This particularly second and essential set of instructions requires the form of a series of chemical turns that in fact determine even if genes are turned on or off, and in the end what the cell will seem like and how it will perform.

Epigenetic effect nature in many methods including the capability of a caterpillar to morph right into a butterfly, although its DNA does not change. Modifications in epigenetic control could also result in cancer.

Lixte Biotechnology Holding Submits IND with FDA

John S. Kovach, M.D., Chair, Board of Directors and Chief executive officer of Lixte Biotechnology Holdings, Inc, introduced the distribution associated with an IND application into the Food and Drug Administration to execute a Phase I trial of their lead, anti-cancer compound, LB-100.

Dr. Kovach said, "We feel that in fact LB-100, a new anti-cancer compound, stops melanoma cells from declaring themselves against usual types of cancer therapies. In pre-clinical animal types of cancer, LB-100 stops cancer cell growth by itself, but also, it substantially enhances the murder of cancer cells by a number of frequently anti-cancer drugs such as Temozlomide, Doxorubicin, and Docetaxel in addition to radiation.

Here in the initial Phase I trial to become conducted at a country wide recognized comprehensive melanoma center, LB-100 will be tested alone and in mixture by using a standard anti-cancer drug.